1. Home
  2. IMMP vs LPA Comparison

IMMP vs LPA Comparison

Compare IMMP & LPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMP
  • LPA
  • Stock Information
  • Founded
  • IMMP 1987
  • LPA 2013
  • Country
  • IMMP Australia
  • LPA United States
  • Employees
  • IMMP N/A
  • LPA N/A
  • Industry
  • IMMP Biotechnology: Pharmaceutical Preparations
  • LPA
  • Sector
  • IMMP Health Care
  • LPA
  • Exchange
  • IMMP Nasdaq
  • LPA Nasdaq
  • Market Cap
  • IMMP 304.0M
  • LPA 310.7M
  • IPO Year
  • IMMP N/A
  • LPA N/A
  • Fundamental
  • Price
  • IMMP $1.85
  • LPA $9.00
  • Analyst Decision
  • IMMP Buy
  • LPA
  • Analyst Count
  • IMMP 2
  • LPA 0
  • Target Price
  • IMMP $8.50
  • LPA N/A
  • AVG Volume (30 Days)
  • IMMP 74.2K
  • LPA 6.1K
  • Earning Date
  • IMMP 03-25-2025
  • LPA 03-25-2025
  • Dividend Yield
  • IMMP N/A
  • LPA N/A
  • EPS Growth
  • IMMP N/A
  • LPA N/A
  • EPS
  • IMMP N/A
  • LPA N/A
  • Revenue
  • IMMP $3,019,249.00
  • LPA $44,311,428.00
  • Revenue This Year
  • IMMP N/A
  • LPA N/A
  • Revenue Next Year
  • IMMP $20.28
  • LPA N/A
  • P/E Ratio
  • IMMP N/A
  • LPA N/A
  • Revenue Growth
  • IMMP 24.11
  • LPA 22.46
  • 52 Week Low
  • IMMP $1.65
  • LPA $6.00
  • 52 Week High
  • IMMP $3.34
  • LPA $525.00
  • Technical
  • Relative Strength Index (RSI)
  • IMMP 48.75
  • LPA N/A
  • Support Level
  • IMMP $1.65
  • LPA N/A
  • Resistance Level
  • IMMP $1.88
  • LPA N/A
  • Average True Range (ATR)
  • IMMP 0.09
  • LPA 0.00
  • MACD
  • IMMP 0.01
  • LPA 0.00
  • Stochastic Oscillator
  • IMMP 65.00
  • LPA 0.00

About IMMP Immutep Limited

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.

Share on Social Networks: